VA
OKUR

Verdad Advisers’s OnKure Therapeutics OKUR Stock Holding History

Verdad Advisers’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
+28,660
New +$123K 0.13% 174

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verdad Advisers's OKUR Position: Q2 2026 in Review

Verdad Advisers opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 28,660 shares worth $131K. The stake represents 0.13% of the portfolio and ranks #174 among its holdings.

75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Verdad Advisers held 28,660 shares of OnKure Therapeutics worth $131K as of Q2 2026.
  • OnKure Therapeutics was a new Verdad Advisers position in Q2 2026.
  • OnKure Therapeutics made up 0.13% of Verdad Advisers's portfolio in Q2 2026, its #174 holding.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.